Study wrapper · #942
Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
Abdelrahman RM, Musa TH, Arbab IA, et al. Journal of obesity. 2025.
DOI: 10.1155/jobe/9919810PubMed: 41333115
Editor's note
This review surveys the current and near-future GLP-1 landscape for obesity, discussing tolerability, access, and expanding indications. Semaglutide and tirzepatide are covered as approved agents with retatrutide among the pipeline drugs. A broad background piece with some forward-looking speculation.
Plain-language abstract
A narrative review of GLP-1 receptor agonists for obesity, covering efficacy, safety, adherence challenges, and emerging agents including semaglutide, tirzepatide, and retatrutide.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026